|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:R03DX05
|
|
gptkbp:brand
|
gptkb:Xolair
|
|
gptkbp:CASNumber
|
gptkb:242138-07-4
|
|
gptkbp:contraindication
|
hypersensitivity to omalizumab
|
|
gptkbp:drugClass
|
anti-IgE antibody
|
|
gptkbp:form
|
lyophilized powder
pre-filled syringe
|
|
gptkbp:genericName
|
gptkb:omalizumab
|
|
gptkbp:halfLife
|
~26 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xolair
|
|
gptkbp:indication
|
gptkb:chronic_idiopathic_urticaria
nasal polyps
moderate to severe persistent asthma
|
|
gptkbp:legalStatus
|
Rx-only
|
|
gptkbp:macromoleculeType
|
gptkb:immunoglobulin_E_(IgE)
|
|
gptkbp:manufacturer
|
gptkb:Genentech
gptkb:Novartis
|
|
gptkbp:mechanismOfAction
|
binds to IgE
inhibits allergic response
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
headache
injection site reaction
anaphylaxis
|
|
gptkbp:usedIn
|
immunology
allergy treatment
|
|
gptkbp:bfsParent
|
gptkb:Novartis
|
|
gptkbp:bfsLayer
|
4
|